Interview with Philippe Ranty, Managing Director, Actavis France
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
Address: Centre d’Affaires la Boursidière BP 50, 92357 le Plessis-Robinson, France ,France
Tel: +33 1 40 83 77 77
Web: http://www.actavis.com/en/default.htm
Actavis is the fifth largest generics company worldwide. In France, Actavis has been present since acquiring Labo Torlan in 2007. The groups domestic strategy can be characterized by three elements: a large product offer, a new approach of quality and customer relationship management and a strong involvement in sustainable development.
Actavis serves the French market through its Actavis France, Arrow Generiques and Medis businesses. The Company develops, manufactures and distributes a broad portfolio of products, including generic drugs for retail and hospital markets, OTC, cosmetics and mature products.
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
Edouard Bieth, managing director of Tillotts Pharma in France, discusses the opportunities and challenges of opening an affiliate in the country and the uniqueness of Tillotts’ specialization in gastrointestinal drugs.…
The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure clinical compliance, ethical behaviour and the well-being of the nation. The health sector is…
Arnaud Gobet, president of Innothera, discusses how the company balances its unique and diverse offering of medical devices, hygiene and protection products and pharmaceuticals, Innothera’s burgeoning international footprint and the…
Josephine Yang Comiskey, president of GSK France, gives insights into GSK’s corporate culture, portfolio and priorities in France. She also highlights the need for collaboration and a better dialogue between…
Pierre Banzet, CEO of French CDMO Groupe SYNERLAB, shares how the group has developed over the past three years and discloses his strategy for generating specialty production knowledge as well…
On February 4 in Paris, Minister of Health and Solidarity Agnès Buzyn, Minister of Higher Education, Research and Innovation Frédérique Vidal, Secretary of State to the Minister of Economy and…
Stéphane Mathieu CEO for SIGVARIS GROUP’s Europe, South & West operations, discusses taking on a unique challenge as the company pivots towards becoming a fully-fledged health technology provider, and what…
Frank Margain, chairman of Paris Region Entreprises, the ‘Invest in Paris Region’ promotion agency, discusses the importance of the life sciences sector for the Paris Region (Ile-de-France in French) and…
Emmanuelle Quilès, CEO of Janssen France, speaks about how she joined the American multinational with the ambition to bring digitalization and transform the organization from the inside. Quilès goes on…
Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the high-risk field despite the withdrawal of many industry players, the strategy…
Franck Hamalian, general manager of the French affiliate of Aspen, a specialty and branded multinational pharmaceutical company from South Africa, discusses the Group’s unique business model which revolves around strategic…
Newly-appointed general manager of UCB France, Catherine Rives, discusses what drew her back to the company after time away, market access issues in France and the future of personalized medicine.…
See our Cookie Privacy Policy Here
